Mangalam Drugs And Organics Limited
Incorporated in 1977, Mangalam Drugs& Organics Ltd manufactures Active Pharmaceutical Ingredients andIntermediates
What Mangalam files
- Others55
- Board Meeting20
- Important18
- Results6
- Pledging5
- Updates4
Mangalam Drugs & Organics announced its financial results for the year ended March 31, 2026. 1. **Financial Performance:** Total revenue from operations for the year declined by 26.89% year-over-year, settling at 232.13 Cr compared to 317.58 Cr previously. The company's primary business is 'Manufacturing of Bulk Drugs'. 2. **Profitability and...
Mangalam Drugs & Organics has informed of a delay in submitting its unaudited financial results for the quarter ended September 30, 2025. The company cited "unavoidable circumstances" preventing finalization. It will make sincere efforts to complete the results as soon as possible, with a Board meeting intimation to follow for...
Here's a summary of Mangalam Drugs and Organics Limited's latest financial results: 1) **Revenue Performance:** Mangalam Drugs and Organics (MDOL) reported a **25.19% YoY drop** in total operating revenue for the quarter, landing at **Rs 57.35 Cr** compared to Rs 76.54 Cr in the same period last year. The company...
**Revenue Performance:** Mangalam Drugs and Organics Ltd. has announced a board meeting on August 7, 2025, where it approved the financial results for the quarter ended June 30, 2025. The company reported a significant drop in total revenue from operations, which stood at Rs 57.21 Cr for Q1 FY26, down...
Mangalam Drugs & Organics has announced a board meeting on May 17, 2025, to approve the financial results for the quarter and half-year ended March 31, 2025. 1) Revenue Performance: Consolidated total revenue stood at ₹390 Cr, marking an 8% YoY increase. Growth was driven by capacity expansions in the...